EHMT2 and small cell lung carcinoma: In these T-SCLC cell line models, genetic knockdown or pharmacological inhibition of EHMT2 reversed the NE phenotype of resistant cells and resensitized cells to EGFR inhibitors [48], implicating EHMT2 as a key driver of NE conversion in this context.